Hughes-Stovin syndrome

Revision as of 15:02, 31 October 2012 by Prashanthsaddala (talk | contribs) (Created page with "__NOTOC__ {{SI}} {{CMG}} ==Overview== 'Hughes-Stovin syndrome is a rare clinical condition characterized by multiple pulmonary artery aneurysms and peripheral venous [...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for Hughes-Stovin syndrome

Articles

Most recent articles on Hughes-Stovin syndrome

Most cited articles on Hughes-Stovin syndrome

Review articles on Hughes-Stovin syndrome

Articles on Hughes-Stovin syndrome in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Hughes-Stovin syndrome

Images of Hughes-Stovin syndrome

Photos of Hughes-Stovin syndrome

Podcasts & MP3s on Hughes-Stovin syndrome

Videos on Hughes-Stovin syndrome

Evidence Based Medicine

Cochrane Collaboration on Hughes-Stovin syndrome

Bandolier on Hughes-Stovin syndrome

TRIP on Hughes-Stovin syndrome

Clinical Trials

Ongoing Trials on Hughes-Stovin syndrome at Clinical Trials.gov

Trial results on Hughes-Stovin syndrome

Clinical Trials on Hughes-Stovin syndrome at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Hughes-Stovin syndrome

NICE Guidance on Hughes-Stovin syndrome

NHS PRODIGY Guidance

FDA on Hughes-Stovin syndrome

CDC on Hughes-Stovin syndrome

Books

Books on Hughes-Stovin syndrome

News

Hughes-Stovin syndrome in the news

Be alerted to news on Hughes-Stovin syndrome

News trends on Hughes-Stovin syndrome

Commentary

Blogs on Hughes-Stovin syndrome

Definitions

Definitions of Hughes-Stovin syndrome

Patient Resources / Community

Patient resources on Hughes-Stovin syndrome

Discussion groups on Hughes-Stovin syndrome

Patient Handouts on Hughes-Stovin syndrome

Directions to Hospitals Treating Hughes-Stovin syndrome

Risk calculators and risk factors for Hughes-Stovin syndrome

Healthcare Provider Resources

Symptoms of Hughes-Stovin syndrome

Causes & Risk Factors for Hughes-Stovin syndrome

Diagnostic studies for Hughes-Stovin syndrome

Treatment of Hughes-Stovin syndrome

Continuing Medical Education (CME)

CME Programs on Hughes-Stovin syndrome

International

Hughes-Stovin syndrome en Espanol

Hughes-Stovin syndrome en Francais

Business

Hughes-Stovin syndrome in the Marketplace

Patents on Hughes-Stovin syndrome

Experimental / Informatics

List of terms related to Hughes-Stovin syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

'Hughes-Stovin syndrome is a rare clinical condition characterized by multiple pulmonary artery aneurysms and peripheral venous thrombosis, first described in 1959 [1]. Patients, mostly men aged 12–40 years may present with haemoptysis, cough, dyspnea, chest pain, and signs of pulmonary hypertension. Other associated features reported in Hughes-Stovin syndrome include fever and elevated intracranial hypertension. Since its first description, there have been only a few reports of its occurrence in the English medical literature [2]. Aneurysms usually involve the pulmonary arteries and the bronchial arteries resulting in subsequent haemoptysis. However they can occur anywhere in systematic circulation [3]. Recurrent phlebitis also commonly involves the large vessels resulting in thrombus formation. In general there is a thrombus formation predisposition affecting the peripheral veins. Thrombosis of the vena cava and of the right atrium has also been described [2,4]. Histologic studies show destruction of the arterial wall and perivascular lymphomonocytic infiltration of capillaries and venules [5].

Pathogenesis

The pathogenesis of Hughes-Stovin syndrome is not known. The current consensus opinion is that Hughes-Stovin syndrome results from a vasculitis similar to that implicated in Behçet's disease [2]. Vasculitis in Behçet's disease results in arterial occlusion, arterial aneurysm, venous occlusion, and varices [6], indicating systemic vessel involvement. Furthermore, it is very likely that Hughes-Stovin syndrome represents a cardiovascular manifestation of Behçet disease, since in both clinical entities pulmonary aneurysms are characteristic clinical features [7]. However other clinical presentations can overlap significantly; both are more common in young men, the pulmonary manifestations of both can be identical, and the histology of the aneurysms in both entities can be similar [8].

Regardless the presence of deep venous thrombosis, the pulmonary artery thrombi may originate in situ, secondary to the pulmonary artery wall inflammation. On initial CT images a rim of enhancement at the filling defects may be depicted; this finding is consistent with inflammation – a finding that is not usually seen in acute or chronic pulmonary embolism [9]. Similarly, the pathogenesis of pulmonary artery aneurysms in Hughes-Stovin syndrome has been attributed to weakening of the vessel wall due to inflammation, which corresponds well to the observation by Ketchum et al, that the aneurysms develop at the locations of prior thrombus and abnormal enhancement [9]. Hughes and Stovin's original theory [1] suggested that degenerative bronchial arteries lead to changes in the vasa vasorum of the pulmonary arteries and the development of aneurysms. The volume-rendered CT images according to Ketchum et al show prominent and tortuous bronchial artery branches that apparently supply a web of smaller vessels at the sites of pulmonary artery wall inflammation even before the actual aneurysm formation [9]. Similarly Mahlo et al. [10] and Herb et al. [3] performed digital subtraction angiography of the bronchial arteries and noted distorted and dilated bronchial arteries with convoluted small branches, findings that correspond to Hughes and Stovin's original theory [9].

Haemoptysis remains a leading cause of death in patients with Behçet disease. Similarly, Hughes-Stovin syndrome is often fatal as a result of massive haemoptysis due to pulmonary/bronchial arterial aneurysm rupture. However systemic bronchial artery hypertrophy secondary to ischemia related to the pulmonary artery occlusion could also be the origin of bleeding [3,10]. Finally, haemoptysis could be attributed secondary to both pre-mentioned mechanisms [11].

Conventional angiography can be used for better evaluation of the pulmonary aneurysms and assessment of angiodysplastic bronchial arteries in Hughes-Stovin syndrome.

However, it cannot be performed in all patients with venous thromboses. Contrast-Enhanced MRA and Contrast-Enhanced MDCTA may provide an alternative [12-14] while 3D volume rendering analysis can ideally visualize the presence of an increased number of morphologically abnormal bronchial arteries even before aneurysm formation [9]. In fact it is reported that multi-detector row helical CT angiography provides more precise depiction of bronchial and nonbronchial systemic arteries than does conventional angiography [14].

The syndrome is most often treated by immunosuppressant, either systemic corticosteroids or cytotoxic agents (a combination of cyclophosphamide and glucocorticoids), in patients without or with small amount of hemoptysis in order to stabilize the pulmonary artery aneurysms [2], or even make them disappear [15]. If pulmonary embolism is present a therapeutic dilemma is often posed in using anticoagulants. Anticoagulation may prevent the progression of pulmonary embolism and resolve vein thrombi, but since it increases the risk and severity of haemoptysis, it is contraindicated. Surgical resection of the affected segments of the lung is to be considered in cases of high risk rupture aneurysms limited to one segment or one lung [7]. However, the high morbidity and mortality associated with surgery, and the frequent bilaterality and multifocality of the pulmonary artery aneurysms at the time of diagnosis, makes transcatheter embolization an alternative to surgery in most cases [2]. Identification of aneurysms in the bronchial arteries should be treated by bronchial artery embolization [3]. Even enlargement of bronchial arteries when recognized, should be treated [11].

Symptoms

  • Multiple pulmonary aneurysms[1]
  • Peripheral venous thrombosis[1]
  • Recurrent fever[1]
  • Chills[1]
  • Haemoptysis[1]
  • Cough[1]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 Chalazonitis; et al. (January 29, 2009). "Hughes-Stovin Syndrome: a case report and review of the literature". National Center for Biotechnology Information. Retrieved November 5 2011. Check date values in: |accessdate= (help)

Template:Disease-stub

cs:Hughesův-Stovinův syndrom ko:휴-스토빈 증후군 it:Sindrome di Hughes-Stovin